Respiratory Syncytial Virus Disease Burden and Nirsevimab Effectiveness in Young Children From 2023-2024.
Moline HL, Toepfer AP, Tannis A, Weinberg GA, Staat MA, Halasa NB, Boom JA, Klein EJ, Williams JV, Schuster JE, Goldstein L, McKeever ER, Kalman C, Paden C, Atherton L, Aggarwal M, Roychoudhury P, Piedra PA, Sahni LC, Stewart LS, Selvarangan R, Michaels MG, Schlaudecker EP, Szilagyi PG, Englund JA, Clopper BR, Thornburg NJ, Derado G, McMorrow ML, Dawood FS; New Vaccine Surveillance Network Collaborators.
Moline HL, et al. Among authors: aggarwal m.
JAMA Pediatr. 2024 Dec 9:e245572. doi: 10.1001/jamapediatrics.2024.5572. Online ahead of print.
JAMA Pediatr. 2024.
PMID: 39652359